Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Maximum Strength Pepcid AC Approval Calls For Postmarketing Study

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson/Merck is required to submit a protocol by late March 2004 for a postmarket study on Pepcid AC (famotidine) (10 mg) and new Maximum Strength Pepcid AC (20 mg), following FDA approval of the latter Sept. 24

You may also be interested in...



Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts

The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.

Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts

The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.

Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts

The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS096012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel